Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245673 · ClinicalTrials.gov registry record · Phase 2
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01245673: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01245673 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01245673, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments is able to control the myeloma.
Interventions
- BIOLOGICAL Prevnar- Pneumococcal Conjugate Vaccine (PCV)
- OTHER Activated/costimulated autologous T-cell
- DRUG Revlamid® (Lenalidomide)
- BIOLOGICAL MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-05-10 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01245673
The ClinicalTrials.gov registry entry for NCT01245673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prevnar- Pneumococcal Conjugate Vaccine (PCV) is the first listed.
NCT01245673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01245673 about?
NCT01245673 is a clinical study titled "Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma". One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments ...
What is the current status of trial NCT01245673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2011-05-10. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01245673?
The interventions under investigation include: Prevnar- Pneumococcal Conjugate Vaccine (PCV) (BIOLOGICAL), Activated/costimulated autologous T-cell (OTHER), Revlamid® (Lenalidomide) (DRUG), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01245673?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.